Nikhil Kamath
Group Medical Director, Global Development Leader (Nephrology Rheumatology) @Roche
Signup · Get unlimited contacts
WORK HISTORY
Group Medical Director, Global Development Leader (Nephrology Rheumatology) @Roche
Asset Leadership: Accountable for the global development strategy and execution of the Antisense Oligonucleotide (Factor B inhibitor) program in IgA Nephropathy.Accountable for matrix leadership of cross functional team.Strategic Expansion: Driving indication expansion strategies that balance scientific innovation with commercial constraints, ensuring a \"scientifically and clinically driven\" approach that also appreciates commercial aspects.Proactive regulatory engagement: oversaw numerous health authority interactions across all key regions to enable strategy optimizationTeam Optimization: Fostered a psychologically safe environment that empowers functional leads to challenge the status quo, resulting in streamlined decision-making.
EDUCATION
Faculty of Pharmaceutical Medicine
Pharmaceutical Medicine
Cardiff University / Prifysgol Caerdydd
Post-graduate course in pharmaceutical medicine
University of Cambridge
Bachelor of Arts, Natural Sciences
Faculty of Pharmaceutical Medicine
Diploma in Pharmaceutical Medicine
UCL
MBBS, Clinical Medicine
University of Cambridge
BA, Natural Sciences
Royal College of Physicians
MRCP
SKILLS
ABOUT NIKHIL KAMATH
Currently, I operate as the \"Asset CMO\" for high-priority immunology and nephrology assets. My role demands ultimate accountability for the asset’s development value proposition—owning the integrated development strategy across Clinical, Regulatory, Safety and Operations to deliver efficient, high quality outcomes.I specialize in bridging the gap between agile innovation and global execution. I successfully led the clinical integration of a small biotech acquisition, stabilizing the transition and maximizing the asset\'s value within a complex global framework.Speed is a function of clarity. My approach focuses on reducing operational noise to accelerate decision-making. I empower teams to \"radically simplify\" study designs and development plans, removing non-essential complexity to improve recruitment velocity and data quality.I view development through an investor lens. Whether securing non-dilutive funding (e.g, BARDA) or executing rigorous futility analyses to stop programs early and preserve capital, I prioritize data-driven decisions that protect resources and focus effort where it yields the highest return.Therapeutic Focus: Immunology, Nephrology,Rheumatology and Respiratory
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.